IP Library Granted Patent US 9,790,173
Granted Patent B2
US 9,790,173 · App. 15/435,814 · Granted Oct 17, 2017

Alpha-7 nicotinic acetylcholine receptor modulators and uses thereof-I

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,790,173
App. No.
15/435,814
Granted
Oct 17, 2017
Kind
B2
Abstract

The present invention relates to chemical compounds of formula (I), with the substituents as described in the specification, useful in the positive modulation of the alpha 7 nicotinic acetylcholine receptor (α7 nAChR). The invention also relates to the use of these compounds in the treatment or prevention of a broad range of diseases in which the positive modulation of α7 nAChR is advantageous, including neurodegenerative and neuropsychiatric diseases and also neuropathic pain and inflammatory diseases.

Claims (15)

1. A compound represented by formula (Ia′), or a pharmaceutically acceptable salt thereof:

wherein

n is 1;

R 2 is selected from C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, phenyl, F, or Cl;

R 3 is selected from hydrogen, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, F, Cl, or CN; or

R 2 and R 3 together form C 4-9 cycloalkyl or C 4-9 cycloalkenyl;

R 4 is selected from optionally substituted heteroaryl, optionally substituted heterocyclyl, or optionally substituted aryl; and

R 5 is independently selected from hydrogen, or C 1 -C 4 alkyl;

wherein the optional substituents are each independently selected from halogen, C 1-6 alkyl, C 1-6 alkoxy, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 1-6 haloalkoxy, —OH, phenyl, benzyl, phenoxy, benzyloxy, benzoyl, —NH 2 , —NHC 1-4 alkyl, —N(C 1-4 alkyl) 2 , —CN, —NO 2 , mercapto, —P═O(OH)NH 2 , —S(O) 2 NH 2 , —S(O) 2 NHC 1-4 alkyl, —S(O) 2 N(C 1-4 alkyl) 2 , C 1-6 alkylcarbonyl, C 1-6 alkoxycarbonyl, CO 2 H, —S(O)R′″, and —S(O) 2 R″″, wherein R′″ is lower alkyl or cycloalkyl and wherein R″″ is lower alkyl, cycloalkyl or OH.

2. A compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 2 and R 3 are both C 1 -C 3 alkyl (preferably methyl), or R 2 and R 3 together form a C 4 -C 9 cycloalkyl ring.

3. A compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R 2 and R 3 are both F.

4. A compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R 2 and R 3 are both methyl.

5. A compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R 2 is methyl, and R 3 is hydrogen.

6. A compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R 2 and R 3 together form a C 4 -C 9 cycloalkyl ring, preferably cyclopentyl or cyclohexyl ring.

7. A compound or stereoisomer thereof, or a pharmaceutically acceptable salt thereof, represented by the following:

Assignments (1)
MERGER Recorded Aug 8, 2022
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 061102/0145 →